COVID-19: Treatment Timeline and Investment Implications
Potential medical solutions for COVID-19 include testing ability, therapeutics, and vaccines.
Economic confidence will return only once emergency needs related to the virus have been managed and contained.
We are looking at investment opportunities created by the market dislocation.
Most of the United States remains on social restrictions while awaiting possible medical solutions to COVID-19, which has infected over two million people to date globally. The ability to determine immunity to the virus, as well as viable treatment options and ultimately, a vaccine, are needed before social restrictions can end. These are critical first steps to give visibility to the duration of this crisis and its potential impact on economic activity and ultimately, to allow investor confidence to return. There are over 260 programs currently in testing. It is important to note that production is ramping up on many of these options without full-scale clinical trials having been completed. It is difficult to determine what has real potential and what is more noise, and given the fluidity of the situation, that is likely to be the case in the near term. Nonetheless, it is important for investors to understand and keep top of mind.
In the near term, testing is critical to determine which parts of the population can safely return to work and which sections need to continue to physically isolate. There are currently two options for testing:
Molecular diagnostic testing (PCR) is currently in use and is 98% accurate, with an optimal result turnaround time of 24–48 hours. The US has the ability to perform 400,000 tests per day, but the demand is for over one million tests per day. Roche, Abbott Laboratories, and Cepheid are manufacturing the tests, and production is scaling up for millions of tests per week.
Antibody/serological is the other testing option and can identify those who have already been exposed. Recent estimates show that 25% of people who have COVID-19 are asymptomatic. The antibody appears in bloodwork about four to five days post-infection and appears to give immunity for approximately one year. At this time, the Food and Drug Administration (FDA) is allowing the use of serology tests without formal FDA review. Becton Dickinson is the dominant player, and along with several other companies, it is ramping up to provide large-scale testing within the next few months.
Accurate testing is also critically important to fully understand the segment of impacted people. This will give us better insight into how the virus spreads and a better understanding of the true fatality rate. To date, the virus is seen as having a higher fatality rate than those of similar diseases. How that holds as we get a better sense of how many people have been impacted will help give insight into what levels of containment may be necessary.
Therapeutics With no cure currently available, there are several therapeutic options being used and explored:
Antiviral treatments have been the first line of defense against COVID-19, as they can reduce the intensity and duration of the infection. However, they are neither a cure nor a prevention, and it is not known if antivirals work effectively on all segments of the population. Phase 3 clinical studies have begun on Gilead Sciences’ Remdesivir, which was originally developed to treat Ebola. Initial trial results should be available by the end of April.
Anti-inflammatories include existing repurposed drugs that seem to inhibit overactive immune systems. Late-stage clinical trials have begun for Roche’s Actemra, which is being used in China for patients with severe complications. Trial results of Regeneron’s Kevzara should be available by the summer.
Antibodies include both monoclonal and cocktail. Antibody drugs specifically attack the protein in the virus and have worked on patients with Ebola, MERS, and SARS. Several firms, including Regeneron, are looking at the summer for preclinical trials.
Vaccines Vaccines are both the most hoped-for solution and also the riskiest. The typical paradigm for vaccine development involves multiple years of development and trials. With COVID-19, development is happening in overlapping phases to shorten timeframes, and large-scale manufacturing would be concurrent with clinical development. There are multiple early-stage trials in process, both in the US and in China. Any vaccine would need to be both effective and safe to proceed. Both novel and traditional vaccines are being investigated:
Novel – The leading candidate in the US is the mRNA vaccine from Moderna, and a healthy volunteer study began in March. This approach, which uses a piece of COVID-19’s genetic code, or messenger RNA, has not been previously approved by the FDA, and safety issues are a concern. Moderna has the most optimistic timeline, with the possibility of dosages available for frontline health care workers by Q4 2020 and broader distribution available by Q1 2021.
Traditional – Johnson & Johnson is working on a version based on the same technology used for its Ebola vaccine. The company hopes to conduct human testing in the fall, with the capacity to mass-produce broadly one billion doses by mid-2021.
The near-term way out Without a cure or a vaccine currently available, diagnosis is critical when considering a return to normalcy. Discussions about individuals returning to work would need to include identifying those who have immunity and administering both the PCR test and the serological test. While both tests have issues with false negatives, it is hoped that using the tests together will provide a higher level of accuracy.
Some cities and companies are discussing ways to reduce social distancing once a peak in new cases has been reached and proper surveillance infrastructure (similar to what is used for the flu) has been put in place.
Investment opportunities In this environment, how are we approaching investment analysis, and what are some interesting opportunities? There are many factors at play, including the impact the virus has had on the economy and the probable global recession. It is a key factor in our macro positioning, both for broad risk assets and for sector allocations in model portfolios, such as holding an overweight to health care. In our active equity strategies, we have held positions in several of the companies discussed above for some time based on their long-term fundamentals, including their overall development pipeline and portfolio of drugs, as well as their specific relevance to COVID-19 diagnosis and treatment. Looking past the immediate response, here are some of the themes we are monitoring:
The move from private insurance to government programs: with so many unemployed individuals, many will move to government insurer programs, which have a lower reimbursement level. The financial impact of this will need to be examined for insurers, hospitals, and pharmaceutical firms.
Future investments: particularly in hospitals, many of which were ill-prepared and will require huge expenditures. This can be a more sustainable opportunity for equipment suppliers.
Security of supply: manufacturing will likely become more localized to reduce any future disruptions in the supply chain.
Telemedicine: is likely to continue to be popular even after social-distancing rules have been relaxed.
Drug pricing: political issues surrounding drug pricing that have contained valuations will likely go away in the short term.
Market dislocations: including companies that are being punished now, as their products/services are not essential, but are likely to recover once the pandemic subsides.
At State Street Global Advisors, we are keeping an eye on long-term fundamentals and look for diversification, management quality, and balance sheet strength — in addition to sustainable return and growth. This health crisis will have winners and losers, even within health care, so it is important to understand those long-term fundamentals when committing capital. We are monitoring fiscal and monetary policies as we work through these challenging times, mindful of the continued uncertainty of the situation, but we are also looking at opportunities that the market dislocation has created.
The views expressed in this material are the views of Daniel Farley through the period ended April 20th, 2020 and are subject to change based on market and other conditions. This document contains certain statements that may be deemed forward looking statements. Please note that any such statements are not guarantees of any future performance and actual results or developments may differ materially from those projected. Investing involves risk including the risk of loss of principal. Past performance is no guarantee of future results.
The information provided does not constitute investment advice and it should not be relied on as such. It should not be considered a solicitation to buy or an offer to sell a security. It does not take into account any investor’s particular investment objectives, strategies, tax status or investment horizon. You should consult your tax and financial advisor. All material has been obtained from sources believed to be reliable. There is no representation or warranty as to the accuracy of the information and State Street shall have no liability for decisions based on such information.
The whole or any part of this work may not be reproduced, copied or transmitted or any of its contents disclosed to third parties without State Street Global Advisors’ express written consent.
The trademarks and service marks referenced herein are the property of their respective owners. Third party data providers make no warranties or representations of any kind relating to the accuracy, completeness or timeliness of the data and have no liability for damages of any kind relating to the use of such data.
Investing involves risk including the risk of loss of principal.
Issued by State Street Global Advisors, Australia Services Limited (AFSL Number 274900, ABN 16 108 671 441) ("SSGA, ASL"). Registered office: Level 14, 420 George Street, Sydney, NSW 2000, Australia · Telephone: 612 9240-7600 · Web: www.ssga.com.
State Street Global Advisors, Australia Services Limited (ASL) (AFSL Number 274900, ABN 16 108 671 441) is the issuer of interests and the Responsible Entity for the ETFs which are Australian registered managed investment schemes quoted on the AQUA market of the ASX or listed on the ASX. This material is general information only and does not take into account your individual objectives, financial situation or needs and you should consider whether it is appropriate for you. You should seek professional advice and consider the product disclosure document, available at www.ssga.com/au, before deciding whether to acquire or continue to hold units in an ETF. This material should not be considered a solicitation to buy or sell a security. ETFs trade like stocks, are subject to investment risk, fluctuate in market value and may trade at prices above or below the ETF's net asset value. ETFs typically invest by sampling an index, holding a range of securities that, in the aggregate, approximates the full index in terms of key risk factors and other characteristics. This may cause the fund to experience tracking errors relative to performance of the index. Investing involves risk including the risk of loss of principal. Diversification does not ensure a profit or guarantee against loss. Holdings and sectors shown are as of the date indicated and are subject to change. This information should not be considered a recommendation to invest in a particular sector or to buy or sell any security shown. It is not known whether the sectors or securities shown will be profitable in the future. Sector ETF products are also subject to sector risk and non-diversification risk, which generally results in greater price fluctuations than the overall market. SPDR and Standard & Poor's® S&P® indices are trademarks of Standard & Poor's Financial Services LLC and have been licensed for use by State Street Corporation. The Dow Jones Global Select Real Estate Securities Index is a product of S&P Dow Jones Indices LLC and has been licensed for use by State Street Global Advisors, ASL. MSCI indices, the property of MSCI, Inc. ("MSCI"), and ASX®, a registered trademark of ASX Operations Pty Limited, have been licensed for use by State Street Global Advisors, ASL. SPDR products are not sponsored, endorsed, sold or promoted by any of these entities and none of these entities bear any liability with respect to the ETFs or make any representation, warranty or condition regarding the advisability of buying, selling or holding units in the ETFs issued by State Street Global Advisors, ASL. State Street Global Advisors Trust Company (ARBN 619 273 817) is the trustee of, and the issuer of interests in, the SPDR® S&P 500® ETF Trust, an ETF registered with the United States Securities and Exchange Commission under the Investment Company Act of 1940 and principally listed and traded on NYSE Arca, Inc. under the symbol "SPY". State Street Global Advisors, ASL is the AQUA Product Issuer for the CHESS Depositary Interests (or "CDIs") which have been created over units in SPY and are quoted on the AQUA market of the ASX. The whole or any part of this work may not be reproduced, copied or transmitted or any of its contents disclosed to third parties without State Street Global Advisors, ASL's express written consent.